We Analyzed the Future Direction of Athira Pharma Inc. (ATHA), Here is What We Found – News Heater
Home  »  Hot Stocks   »  We Analyzed the Future Direction of Athira Pharma ...

We Analyzed the Future Direction of Athira Pharma Inc. (ATHA), Here is What We Found

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Athira Pharma Inc. (NASDAQ:ATHA) went up by 0.63% from its latest closing price compared to the recent 1-year high of $34.79. The company’s stock price has collected -4.17% of loss in the last five trading sessions. Press Release reported on 11/10/21 that Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update

Is It Worth Investing in Athira Pharma Inc. (NASDAQ :ATHA) Right Now?

Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Athira Pharma Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $39.67, which is $25.21 above the current price. ATHA currently public float of 35.50M and currently shorts hold a 3.30% ratio of that float. Today, the average trading volume of ATHA was 415.54K shares.

ATHA’s Market Performance

ATHA stocks went down by -4.17% for the week, with a monthly jump of 22.96% and a quarterly performance of 40.80%, while its annual performance rate touched -37.94%. The volatility ratio for the week stands at 5.79% while the volatility levels for the past 30 days are set at 7.66% for Athira Pharma Inc.. The simple moving average for the period of the last 20 days is -2.32% for ATHA stocks with a simple moving average of -1.52% for the last 200 days.

Analysts’ Opinion of ATHA

Many brokerage firms have already submitted their reports for ATHA stocks, with Stifel repeating the rating for ATHA by listing it as a “Buy.” The predicted price for ATHA in the upcoming period, according to Stifel is $36 based on the research report published on October 13th of the previous year 2020.

JMP Securities, on the other hand, stated in their research note that they expect to see ATHA reach a price target of $51. The rating they have provided for ATHA stocks is “Mkt Outperform” according to the report published on October 13th, 2020.

Jefferies gave a rating of “Buy” to ATHA, setting the target price at $30 in the report published on October 13th of the previous year.

ATHA Trading at 22.63% from the 50-Day Moving Average

After a stumble in the market that brought ATHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.44% of loss for the given period.

Volatility was left at 7.66%, however, over the last 30 days, the volatility rate increased by 5.79%, as shares surge +22.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.31% upper at present.

During the last 5 trading sessions, ATHA fell by -4.17%, which changed the moving average for the period of 200-days by -37.10% in comparison to the 20-day moving average, which settled at $14.94. In addition, Athira Pharma Inc. saw -57.78% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ATHA starting from PERCEPTIVE ADVISORS LLC, who purchase 311,111 shares at the price of $22.50 back on Jan 25. After this action, PERCEPTIVE ADVISORS LLC now owns 3,425,916 shares of Athira Pharma Inc., valued at $6,999,998 using the latest closing price.

Stock Fundamentals for ATHA

The total capital return value is set at -14.59, while invested capital returns managed to touch -14.56. Equity return is now at value -14.00, with -13.60 for asset returns.

Based on Athira Pharma Inc. (ATHA), the company’s capital structure generated 0.36 points at debt to equity in total, while total debt to capital is 0.36. Total debt to assets is 0.36, with long-term debt to equity ratio resting at 0.32. Finally, the long-term debt to capital ratio is 0.32.

>> 7 Top Picks for the Post-Pandemic Economy <<

The liquidity ratio also appears to be rather interesting for investors as it stands at 43.66.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

A Lesson to Learn: Deere & Company (DE)

Deere & Company (NYSE:DE) went up by 2.66% from its latest closing price compared to the recent 1-year high of $400.34. The company’s stock price

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam